Despite recent insights gained from the effects of targeted deletion of the Finkel-Biskis-Jinkins osteosarcoma oncogene (c-fos), Spleen focus-forming virus (SFFV ) proviral integration 1 (PU.1), microphthalmia-associated transcription factor, NF-κB, and nuclear factor of activated cells cytoplasmic 1 (NFATc1) transcription factor genes, the mechanism underlying transcription factors specifying osteoclast (OC) lineage commitment from monocyte/macrophage remains unclear. To characterize the mechanism by which transcription factors regulate OC lineage commitment, we mapped the critical cis-regulatory element in the promoter of cathepsin K (Ctsk), which is expressed specifically in OCs, and found that CCAAT/enhancer binding protein α (C/EBPα) is the critical cis-regulatory element binding protein. Our results indicate that C/EBPα is highly expressed in pre-OCs and OCs. The combined presence of macrophage colony-stimulating factor and receptor activator of NF-κB ligand significantly induces high C/EBPα expression. Furthermore, C/EBPα −/− newborn mice exhibited impaired osteoclastogenesis, and a severe osteopetrotic phenotype, but unaffected monocyte/macrophage development. Impaired osteoclastogenesis of C/EBPα −/− mouse bone marrow cells can be rescued by c-fos overexpression. Ectopic expression of C/EBPα in mouse bone marrow cells and monocyte/macrophage cells, in the absence of receptor activator of NF-κB ligand, induces expression of receptor activator of NF-κB, c-fos, Nfatc1, and Ctsk, and it reprograms monocyte/macrophage cells to OC-like cells. Our results demonstrate that C/EBPα directly up-regulates c-fos expression. C/EBPα +/− mice exhibit an increase in bone density compared with C/EBPα +/+ controls. These discoveries establish C/EBPα as the key transcriptional regulator of OC lineage commitment, providing a unique therapeutic target for diseases of excessive bone resorption, such as osteoporosis and arthritis.
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cell lineage commitment | gene expression regulation | osteoclast differentiation | bone homeostasis | osteopetrosis phenotype O steoclasts (OCs), bone-resorbing cells, play a key role in normal bone remodeling and in many diseases, such as osteopetrosis, osteoporosis, arthritis, periodontal disease, and certain bone metastases. OCs develop from monocytic precursors from the hematopoietic lineage. Spleen focus-forming virus (SFFV) proviral integration 1 (PU.1) can induce the expression of the macrophage colony-stimulating factor (M-CSF) receptor and is critical for monocyte/macrophage lineage commitment (1) . On receptor activator of NF-κB ligand (RANKL) stimulation and immunoreceptor tyrosine-based activation motif (ITAM) activation, OC precursors undergo further differentiation to mononuclear OCs (2) . RANKL specifically and potently induces nuclear factor of activated T cells cytoplasmic 1 (NFATc1), which is a master regulator of OC differentiation, through both the TNF receptor-associated factor 6 (TRAF6)-NF-κB (p105n) pathway and the Finkel-Biskis-Jinkins osteosarcoma oncogene (c-Fos) pathway (3) (4) (5) (6) (7) . This robust induction of NFATc1 is based on an autoamplifying mechanism effected through persistent calcium signal-mediated activation of NFATc1 (NFATc1 binds to NFAT binding sites on its own promoter, constituting a positive feedback loop) (7) . In the nucleus, NFATc1 cooperates with other transcription factors, such as activator protein-1, PU.1, cAMPresponsive element binding protein, and microphthalmia-associated transcription factor, to induce various OC-specific genes (7, 8) . NFATc1, together with other transcription factors, such as c-fos and NF-κB, drives osteoclastogenesis (2, 5). Peroxisome proliferator-activated receptor γ (PPARγ) is also reported to be important for OC differentiation (9) . Although much has been revealed pertaining to the regulation of terminal differentiation of OCs, the cascade of transcription factors that specifies OC lineage commitment from monocytes/macrophages remains unclear (10) . Indeed, a long-standing challenge remaining in the field is to define the mechanism by which M-CSF acts with RANKL to promote OC differentiation, whereas it promotes macrophage differentiation when acting alone (10) , and to define the factor that regulates OC lineage commitment.
Cathepsin K (Ctsk) is a lysosomal cysteine protease that is abundantly and selectively expressed in OCs (11) .The specific expression of the Ctsk in OCs, as well as its enzymatic properties, implies that it has a key role in normal bone remodeling and in pathological processes, such as osteoporosis, osteoarthritis, and pycnodysostosis (12) . Because expression of Ctsk is OC-specific and induced by RANKL stimulation, we characterized the Ctsk critical cis-regulatory elements (CCREs) to identify the transcription factor(s) that modulate OC-specific gene (e.g., Ctsk) expression and to determine which factor(s) enable monocytes to commit to the OC lineage after RANKL stimulation.
Our research revealed that CCAAT/enhancer binding protein α (C/EBPα) regulates OC cell lineage commitment and differentiation. C/EBPα is a key molecular determinant in myeloid lineage commitment (13, 14) , which drives myeloid differentiation through activation of myeloid target genes and through inhibition of the cell cycle through interactions with regulatory proteins (15, 16) . We characterized C/EBPα as the binding protein of the OC gene Ctsk CCRE. We found that the deletion of C/EBPα in KO mice results in severely blocked osteoclastogenesis and that the overexpression of c-fos rescues osteoclastogenesis when C/EBPα is knocked out. Forced expression of C/EBPα, in the absence of RANKL, induces expression of receptor activator of NF-κB (RANK) and OC genes and reprograms the monocyte/macrophage cell line to OC-like cells. These discoveries establish C/EBPα as the key regulator of OC lineage commitment.
Results
Identification of Mouse Ctsk CCRE and Characterization of CCRE DNA Binding Protein. To understand the transcription factors that modulate OC gene expression and OC differentiation, we characterized the Ctsk CCREs. Our results show that RANKL stimulates Ctsk gene promoter activity and indicate the importance of RANKL in combination with the CCRE (Fig. 1A) . To analyze the −137 to −31 region identified as containing a potential CCRE further, we examined the effect of internal deletions within the promoter-CAT fusion gene (pCCAT)-137 construct on Ctsk activity and found that internal deletions of the sequence between −51 and −34 or between −46 and −41 resulted in the total loss of Ctsk promoter activity compared with the complete pCCAT-137 construct (Fig. 1B) . Thus, we determined that the sequence between −51 and −34 contains a Ctsk CCRE (Fig.  1C ). We performed a gel mobility shift experiment using the 32 Plabeled WT Ctsk oligonucleotide probe in nuclear extracts prepared from mouse OC precursor cell line RAW264.7 cells induced with RANKL, with and without a 100-fold molar excess of unlabeled WT or 10 different mutant oligonucleotides. We found that a 100-fold molar excess of mutants 3 and 6 partially competes, whereas mutants 4 and 5 are completely unable to compete, for the DNA-protein complex, indicating that this core sequence of nucleotides is essential for DNA-protein interaction (Fig. 1D) . We analyzed this sequence using transcription factor binding site database searches and found that it is a C/EBPα binding site (TTCCGCAAT). This indicates that C/EBPα may regulate the CCRE. We also performed DNase I footprint analysis and found that the −51 to −34 region, which contains the C/ EBPα binding site, was protected (Fig. 1E) . To confirm that C/ EBPα binds to this CCRE recognition site, we performed supershift mobility assays using a panel of specific antibodies against different C/EBP family members (Fig. S1 ). The bound proteins only produced supershifted complexes in the presence of C/EBPα antibody, indicating that C/EBPα is involved in the formation of this DNA-protein complex (Fig. S1 ). Together, these data indicate that C/EBPα may be a major component of the OC-specific complex that regulates the Ctsk CCRE.
C/EBPα Is Expressed in Pre-OCs and OCs and Is Induced by RANKL. We next examined the tissue and cellular distribution of C/EBPα mRNA by performing a Northern hybridization assay. Giant cell tumors (GCTs) of bone contain human stromal cells (hSCs), OC-like precursors, and OC-like giant cells. Because OC-like giant cells from GCTs of bone are effectively the same as OCs in bone, we used GCTs and hSCs obtained as previously described (11) . In addition, RANKL-induced mouse bone marrow (MBM), uninduced MBM, rat osteoblast, and a human macrophage cell line (U-937 cells) were used along with C/EBPα +/+ mouse tissues. The human C/EBPα transcript (2.4 kb) and mouse C/EBPα transcript (2.7 kb) used as C/EBPα-cDNA probes for this Northern blot assay are highly specific to C/EBPα. As shown in Fig. 2A , C/EBPα (2.7 kb) was highly expressed in RANKL-induced MBM and C/ EBPα +/+ liver tissue. C/EBPα (2.4 kb) was prominently expressed in GCTs of bone (which contain hSCs, OC-like precursors, and OC-like giant cells) but was not expressed in hSCs ( Fig. 2A) . Furthermore, there was very low C/EBPα expression in U-937 cells, MBM, and mouse kidney and brain tissue. Expression of C/EBPα could not be detected in other tissues in these conditions, but this Inset is the magnified image of the boxed area.
does not exclude a role for C/EBPα in those tissues. In order to characterize C/EBPα expression during OC differentiation, we performed Western blot analysis of C/EBPα expression in MBM cultured with M-CSF (20 ng/mL) alone for 2 d and then stimulated with M-CSF (10 ng/mL)/RANKL (10 ng/mL) for 0-120 h. We found that C/EBPα expression more than doubled after 24 h of stimulation. Interestingly, C/EBPα expression peaked at 48 h but retained high expression thereafter (Fig. 2B) . The dramatic increase in C/EBPα expression early during OC differentiation indicates that C/EBPα may play a critical role in the regulation of OC commitment and OC differentiation. To determine the expression of Ctsk and C/EBP family members (i.e., C/EBPα, C/ EBPβ, C/EBPδ) in situ, OC cells were subjected to immunohistochemical staining (17) . We found strong C/EBPα expression in Ctsk-positive multinucleated OCs and mononuclear pre-OCs in GCTs and C/EBPα +/+ tibiae in a similar pattern of expression as Ctsk (Fig. 2C) . In contrast, C/EBPβ was weakly expressed in TNF receptor-associated protein 1 (TRAP)-positive mononuclear preOCs, and C/EBPδ expression was not detected in GCTs or C/ EBPα +/+ tibiae (Fig. 2C ). Immunofluorescence staining of C/ EBPα +/+ tibiae also revealed that C/EBPα colocalized with Ctsk (Fig. 2D) . The pattern of C/EBPα expression indicates a possible critical function of C/EBPα in OC cell lineage commitment and differentiation.
CEBPα
−/− Newborn Mice Exhibited a Severe Osteopetrotic Phenotype
Due to Impaired Osteoclastogenesis. X-ray analyses revealed that C/EBPα −/− mice have dramatically increased bone density compared with C/EBPα +/+ mice (Fig. 3A) , indicating that C/EBPα
mice have an osteopetrotic phenotype. This is supported by microcomputed tomography analysis, which showed significantly increased bone volume and bone mineral density in C/EBPα −/− femora compared with C/EBPα +/+ femora ( Fig. 3 B and C) . In order to analyze the role of C/EBPα in OCs further, we examined whether a null mutation in C/EBPα alleles affects the differentiation of OCs (17) . Our histochemical stains revealed that C/EBPα −/− mice tibiae have long growth plates and a dramatic reduction in TRAP + OCs compared with C/EBPα +/+ controls (Fig. 3D) . Furthermore, TRAP stains demonstrated that TRAP + multinucleated OCs were not formed in RANKLinduced MBM culture from C/EBPα −/− mice compared with C/EBPα +/+ controls (Fig. 3E ). These data confirm that C/ EBPα −/− mice are osteopetrotic and indicate that this phenotype is mainly due to defective osteoclastogenesis. In order to determine if C/EBPα −/− osteoblasts contribute to the defective osteoclastogenesis observed in C/EBPα −/− mice, we used a coculture system and TRAP stain as we have previously described (17) . We determined that a coculture of calvarial mouse osteoblasts (MOBs) derived from C/EBPα +/+ mice with MBM from C/EBPα −/− mice is unable to rescue osteoclastogenesis (compared with C/EBPα +/+ MOBs with C/EBPα +/+ MBM) (Fig. 3F) . Coculture of C/EBPα −/− MOBs with C/EBPα +/+ MBM revealed that mutant osteoblasts sustain osteoclastogenesis (Fig. 3F) , indicating that osteoblasts lacking C/EBPα do not contribute to the defective osteoclastogenesis in C/EBPα −/− mice. (Table S1) (12, 17, 18) . The RT-qPCR results (Fig. S2 ) suggest that C/EBPα is important for the induction of OC-specific genes and that C/EBPα may suppress macrophage-specific genes. These results were confirmed by Western blot analysis of C/EBPα +/+ and C/EBPα does not involve the IκBα or p38 signaling pathways but that it may directly regulate the c-fos arm of the RANKL signaling pathways to promote osteoclastogenesis.
Bone Numbers. To analyze the role of C/EBPα in bone homeostasis further, we stained C/EBPα +/+ and C/EBPα −/− tibiae sections with Goldner's trichrome stain and performed histomorphometric analysis (using Bioquant software; BIOQUANT Image Analysis Corporation). Compared with C/EBPα +/+ controls, C/EBPα −/− tibiae have growth plates with an extended zone of growth plate and a dramatic increase in mineralized tissue, which indicates osteopetrosis (Fig. 5A) . Histomorphometric analysis revealed that KO of C/EBPα results in increased bone volume, distal and proximal hypertrophic growth plate thickness, and trabecular thickness (Fig. 5B ). Our analyses also revealed that the ratio of OC surface to bone surface and the number of OCs per bone perimeter dramatically decreased in C/ EBPα −/− tibiae compared with C/EBPα +/+ tibiae ( Fig. 5B) , further confirming the important role of C/EBPα in osteoclastogenesis. To determine the importance of the C/EBPα dose in mature animals, we analyzed the bone phenotype in C/EBPα
Femora from heterozygous C/EBPα +/− mice (8 mo of age) exhibit an increase in bone density and an increase in trabecular bone compared with C/EBPα +/+ controls ( Fig. S3 ). Goldner's trichrome stain and histomorphometric analysis indicate that C/EBPα +/− femora have an increase in bone volume/tissue volume and trabecular number and a decrease in OC surface/bone surface and OC number/bone perimeter (Figs. S4 and S5).
C/EBPα
−/− Impaired Osteoclastogenesis Is Rescued by Ectopic Expression of c-fos. In order to confirm if C/EBPα regulates osteoclastogenesis through the c-fos arm of the RANKL signaling pathway, we next investigated whether ectopic expression of cfos using retrovirus-mediated gene transfer could rescue the impaired OC differentiation caused by C/EBPα KO. MBM cells were stimulated with M-CSF/RANKL for OC differentiation analysis. These cultured C/EBPα −/− MBM cells were transduced by pBMN-c-fos or the control retrovirus pBMN-GFP ( Fig. 5 C and D) . Compared with the control, the number of multinucleated OCs present increased more than 20-fold when c-fos was overexpressed in cultured C/EBPα −/− myeloid cells (Fig. 5 C and D) . This indicates that impaired OC differentiation caused by C/EBPα KO can be rescued by ectopic expression of c-fos.
C/EBPα Induces Osteoclastogenesis in the Absence of RANKL and
Activates the c-fos Promoter. To determine the mechanism of C/ EBPα function in OC differentiation and gene expression further, we forced expression of C/EBPα in MBM cells by stimulating MBM with M-CSF alone (Fig. 6) . To express C/EBPα in MBM ectopically, we constructed a retrovirus vector (pBMN-C/ EBPα) that was engineered to express both C/EBPα and GFP. Then, MBM was transduced with the C/EBPα-expressing virus (pBMN-C/EBPα) or with a control virus (pBMN-GFP) as described (3). Western blot analysis demonstrates the effective retrovirus-mediated overexpression of C/EBPα in MBM stimulated with M-CSF alone for 96 h (Fig. 6A ). The expression of C/ EBPα increased significantly after 96 h of M-CSF stimulation (Fig. 6A) . At the 96-h time point, there is a surprising marked increase in the number of TRAP + multinucleated OCs when C/ EBPα is overexpressed compared with the control group even in the absence of RANKL stimulation. This underscores the important role of C/EBPα in osteoclastogenesis (Fig. 6B ). Through qPCR, it was determined that the expression of markers common for macrophages and OCs (e.g., RANK, Traf6), key OC genes (e.g., Nfatc1, c-fos, acid phosphatase 5 (Acp5), matrix metallopeptidase 9 (Mmp9), Ctsk), and C/EBPα increased in the pBMN-C/EBPα transfected group (Fig. 6C ). These data indicate that C/EBPα overexpression in the absence of RANKL stimulation can induce the formation of TRAP + multinucleated cells ( Fig. 6 B and C) . Because our results showed that overexpression of c-Fos can rescue the OC defect of C/EBPα −/− cells (Fig. 5C) , it is important to determine if the c-fos promoter has C/EBPα binding sites. Accordingly, we performed ChIP assays with MBM stimulated with RANKL to generate mature OCs and found that C/EBPα directly binds regulatory sequences on the c-fos promoters (Fig. 6D ) and activates c-fos expression (Fig. 6E) . The truncated c-fos promoters were induced by C/EBPα, indicating the presence of two C/EBPα binding sites (Fig. 6F ).
Ectopic Expression of C/EBPα Reprograms the Monocyte/Macrophage
Cell Line to OC-Like Cells in the Absence of RANKL. To question whether ectopic expression of C/EBPα can reprogram the monocyte/macrophage cell line RAW264.7 cells to OC-like cells in the absence of RANKL, we ectopically expressed C/EBPα in RAW264.7 cells by using pcDNA3.1-C/EBPα or the vector control pcDNA3.1 (Fig. 7 A-D) . Western blot analysis demonstrated the effective overexpression of C/EBPα by the plasmid stable transfection approach (Fig. 7A) . Similarly, TRAP staining revealed that TRAP + OCs developed when C/EBPα was overexpressed in the absence of RANKL stimulation (Fig. 7B ). In addition, Ctsk immunostaining demonstrated that C/EBPα overexpression in the absence of RANKL stimulation still resulted in the expression of the OC marker gene Ctsk (Fig. 7B) . C/EBPα overexpression reduced the expression of F4/80, which is a macrophage marker gene. Semi-qPCR of c-fos, Ctsk, Acp5, and Nfatc1 also demonstrated that C/EBPα overexpression increases the expression of key OC genes even in the absence of RANKL (Fig. 7C) . We found that C/EBPα overexpression increased the expression of genes important for OC lineage commitment and differentiation (e.g., Ctsk, PU.1, c-fos, CD115, Traf6, CD11b, Acp5, Nfatc1, Mmp9, Pparγ, CD68, RANK) (9) (Fig. 7D) through qPCR analysis of gene expression. Expression of C/EBPβ increased slightly when C/EBPα was overexpressed in uninduced RAW264.7 cells (Fig. 7D ).
Discussion
In this study, we demonstrated that C/EBPα expression is essential for OC lineage commitment but that it may not be essential for macrophage differentiation. Importantly, forced expression of C/ EBPα in MBM and RAW264.7 cells induced the expression of OC marker genes in the absence of RANKL stimulation (Figs. 6 and 7), which demonstrates that high expression of C/EBPα is sufficient for OC lineage commitment. This study filled the gap in our understanding of how transcription factor(s) specify OC lineage commitment from monocyte/macrophage cells.
C/EBPα Expression Is Essential for OC Lineage Commitment but May
Not Be Essential for Macrophage Differentiation. We sought insight into the mechanism underlying C/EBPα's role in OC differentiation. Specifically, it is important to clarify if C/EBPα expression is important for OC lineage commitment alone or if it is also important for monocyte/macrophage differentiation because OCs are multinucleated cells derived from hematopoietic precursors of the monocyte/macrophage series. Feng et al. (19) discovered that the combined expression of PU.1 and C/EBPα is sufficient to activate a myeloid program in fibroblasts, which are derived from mesenchymal stem cells, and to induce a macrophage-like phenotype. It has also been shown that enforced expression of C/EBPα and C/EBPβ in B cells leads to their rapid and efficient reprogramming into macrophages (20) . Di Tullio et al. (21) recently clarified that this C/EBPα-induced transdifferentiation of pre-B cells into macrophages involves no overt retrodifferentiation. These studies indicate that C/EBPα is important for monocyte/macrophage differentiation. It has been determined that the loss of C/EBPα gene expression in hematopoietic progenitor cells results in a block in differentiation at the common myeloid progenitor and granulocyte/macrophage progenitor stage of development (22, 23) , indicating that C/EBPα expression is important for the development of macrophage CFUs. There is some controversy regarding the requirement of C/EBPα for macrophage development (22, 23) . Heath et al. (23) demonstrated that there was a defect in macrophage development in mice that received transplants of C/EBPα −/− fetal liver cells and that C/EBPα −/− fetal liver cells had decreased M-CSF receptor (Cd115). In contrast, Zhang et al. (22) determined that circulating blood and hematopoietic organs from C/EBPα −/− mice did not lack monocytes or macrophages and that there was no defect in the M-CSF receptor. Consistent with the study by Zhang et al. (22) , our analysis of C/EBPα −/− fetal liver cells, C/EBPα −/− tibiae, and MBM-derived monocyte/macrophage cells indicates that C/ EBPα is not essential for macrophage differentiation (Figs. S6-S8 ). These contrasting results are likely due to differences in the experimental systems utilized, such as C/EBPα −/− mice and mice transplanted with C/EBPα −/− fetal liver cells.
C/EBPα Is a Major Regulator of OC Lineage Commitment but Is Not
Sufficient for Terminal OC Differentiation. C-fos functions downstream of RANKL signaling and plays an essential function in the developmental stage from monocyte/macrophage precursors to mature OCs (5). C-fos is also important for the expression of Nfactc1, which is a regulator of terminal differentiation of OCs (3). Importantly, forced expression of C/EBPα, even in the absence of RANKL stimulation, induced the expression of these key OC transcription factors (e.g., c-fos, Nfatc1) and PU.1 (24) (Fig. 6 ). Our data indicate that C/EBPα may directly regulate c-fos to promote osteoclastogenesis. We determined that the c-fos promoter has two C/EBPα binding sites (Fig. 6D ) and that C/EBPα may activate the c-fos promoter through the two C/ EBPα binding sites (Fig 6 E and F) . Notably, our results indicate that C/EBPα modulates both OC lineage commitment and terminal OC differentiation. Indeed, C/EBPα binding sites are present at both the c-fos promoter and the Ctsk promoter, the latter of which is a gene expressed by committed OCs. In addition, ectopic expression of C/EBPα induces upregulation of both early and late OC markers. Thus, these findings demonstrate that high expression of C/EBPα alone is sufficient for OC lineage commitment and that C/EBPα also modulates terminal OC differentiation.
Potential Mechanism Underlying C/EBPα Is Induced by RANKL. How C/EBPα is induced by RANKL is unclear. However, NF-κB, which is induced by RANKL, regulates C/EBPα expression in myeloid cells. It is thus possible that RANKL induces NF-κB expression, which, in turn, activates C/EBPα expression. It was noted that C/EBPα overexpression largely increased RANK (RANKL receptor) expression (Figs. 6C and 7D) . Thus, another way that C/EBPα may be induced by RANKL (ligand) is through a selfamplification pathway. We suspect that C/EBPα upregulates the expression of receptor RANK, which allows for increased binding of RANKL and triggers the cascade of transcription factors specifying OC lineage commitment. Importantly, our research indicates that a threshold level of C/ EBPα expression is an important component in the mechanism by which M-CSF acts with RANKL to promote OC differentiation, whereas it promotes macrophage differentiation when it acts alone. Thus, this study provides essential insight into the long-standing question of how RANKL promotes OC differentiation. These findings expand the existing view of the role of C/EBPα in bone homeostasis beyond its role in lineage allocation of mesenchymal stem cells and macrophage cells to include a direct and specific role in OC lineage commitment from monocyte/macrophage cells. C/ EBPα may be an ideal target for treating osteolytic diseases.
Materials and Methods
Ctsk Promoter CAT Constructs. A Ctsk pCCAT containing a 1,505-bp XbaI/ EcoRI fragment (−1,474 to −31, numbered relative to the cap site) of the mouse Ctsk 5′-flanking region was used as a starting point for deletion analysis. The sizes of series of 5′ deletions generated were approximated by electrophoresis in a 3:1 NuSieve-agarose gel (Lonza) or, in selected cases, by DNA sequence analysis with the dideoxy chain termination method.
Forced Expression. We used a retrovirus system to express c-fos ectopically, as described previously (17), in C/EBPα −/− myeloid cells cultured with M-CSF/ RANKL to induce osteoclastogenesis. We similarly used a retrovirus system to express C/EBPα ectopically in RANKL-induced C/EBPα +/+ MBM as described previously (17) . C/EBPα was also overexpressed in uninduced RAW264.7 cells by stable transfection.
Statistical Analysis and Data Quantification Analysis. Experimental data are reported as mean ± SD of triplicate independent samples. Data were analyzed with the two-tailed Student's t test. P values <0.05 were considered significant. Data quantification analyses were performed using the National Institutes of Health ImageJ program as described (12, 17) (*P < 0.05 and **P < 0.01 throughout the paper). Additional details are provided in SI Materials and Methods. ) mice, which were a gift from Gretchen J. Darlington (1) . Heterozygous C/EBPα +/− male mice were crossed with C/EBPα +/− female mice to obtain C/EBPα −/− and C/EBPα +/+ (control) mice. Mice were bred in-house and killed by CO 2 asphyxiation. Samples of organs and tissues were obtained from newborn mice, including mouse bone marrow (MBM), bone, brain, kidney, liver, and muscle.
Supporting Information
Cells and Cell Culture. Mature osteoclasts (OCs) in primary culture were generated from MBM as described (2) (3) (4) . Briefly, MBM was obtained from the tibiae and femora of 6-wk-old female WT C/EBPα +/+ mice as described (5, 6). Although constitutive C/EBPα deletion results in mortality within a few hours of birth (1), we were able to extract MBM from newborn C/EBPα +/+ and C/EBPα M dexamethasone as described previously (7) . Primary calvarial osteoblasts were isolated from C/EBPα +/+ and C/EBPα −/− mice on postnatal day 1 as we previously described (7) .
C/EBPα +/+ and C/EBPα −/− spleen cells were cultured with M-CSF (20 ng/mL) alone for 48 h and were then stimulated with M-CSF (10 ng/mL)/RANKL (10 ng/mL) to generate OC-like cells as we previously described (4, (7) (8) (9) . Alternatively, spleen cells were stimulated with 20 ng/mL M-CSF alone to generate monocyte/ macrophage-like cells as described previously (4, (7) (8) (9) .
C/EBPα +/+ and C/EBPα −/− livers were harvested on embryonic days 17.5-18 and cut to small pieces and lysised with 0.05% 1X trypsin/EDTA (Invitrogen) to harvest single cells. Harvested single cells were reseeded in culture dishes and cultured with RANKL/M-CSF as described above to induce OC differentiation. The mouse OC precursor cell line RAW264.7 obtained from the American Type Culture Collection was treated with M-CSF/RANKL to induce OC differentiation as we previously described (4) .
Rat osteoblast cells were derived from calvaria as described previously (7) . Giant cell tumors (GCTs) of bone contain human stromal cells (hSCs), OC-like precursors, and OC-like giant cells. Because OC-like giant cells from GCTs of bone are effectively the same as OCs in bone, we used GCTs and hSCs obtained from GCTs as previously described (10) . The human macrophage (U-937) cell line was purchased from the American Type Culture Collection.
Cathepsin K Promoter CAT Constructs. We characterized the Cathepsin K (Ctsk) promoter as described (11) . The XbaI/EcoRI fragment was subcloned into a pBluescript KS vector (Stratagene) and digested with KpnI/SmaI before insertion of the gene-vector fragment into pCAT-3 Basic Reporter Vector (Promega) to produce pCCAT-1474. The pCCAT-1474 was digested with KpnI and EcoRV, and the product was subjected to controlled 5′ → 3′ digestion with exonuclease III using Erase-a-Base Systems (Promega). The sizes of series of 5′ deletions generated were approximated by electrophoresis in a 3:1 NuSieve-agarose gel (Lonza) or, in selected cases, by DNA sequence analysis with the dideoxy chain termination method.
Cell Transfection and CAT Assay. To determine 5′-flanking regulatory activity, constructs were transfected into RANKLinduced RAW264.7 cells using lipofectamine reagent (BRL) as described (12) . The transfected RAW264.7 cells induced to OCs were tested for differential expression of CAT activity as described (13) . CAT activity in transfected cultures is standardized by normalization to β-gal activity and the protein concentration of cell extracts using a protein assay kit (BioRad) as described (10, 14) . In all experiments, constructs were tested in duplicate or triplicate.
Site-Directed Mutagenesis. Site-directed mutant constructs were created as previously described (10, 14) . In brief, a SpeI restriction site was introduced into pCCAT-137 in the mutant fusion gene as indicated in Fig. 1B . The SpeI fragment from the mutant gene was isolated and cloned into the identical site in pCCAT-137.
Electrophoretic Mobility Shift Assay. Nuclear extracts were prepared as previously described (15) . Gel retardation assays were carried out as described with slight modification (10, 14) . For the electrophoretic mobility shift assay, double-stranded oligonucleotides encoding the −53 to −30 region of the Ctsk promoter were end-labeled with 32 P and used as probes. Competition experiments were performed with a mixture of nuclear extract, and the 32 P-labeled −53 to −30 WT Ctsk promoter oligonucleotide probe was incubated with unlabeled competitors (e.g., −53 to −30 WT Ctsk promoter oligonucleotide, mutant oligonucleotides, activator protein-1 oligonucleotide). Ten mutant oligonucleotides (shown in Fig. 1D ) were synthesized with 2-bp substitutions of the −53 to −30 WT Ctsk promoter sequence AGTTGACTTCCG-CAATCCTTACCG. Mixtures were incubated for 20 min on ice, loaded onto a 4% (vol/vol) nondenaturing polyacrylamide gel, and subjected to electrophoresis. Supershift mobility assays were carried out with antibodies against C/EBPα, C/EBPβ, or C/EBPδ (Santa Cruz Biotechnology) in order to define the factor that binds the critical cis-regulatory element recognition site.
DNase I Footprint Analysis. We performed a DNase I footprint analysis as previously described (14) . Nuclear extracts from RANKL-induced RAW264.7 cells were prepared by the method of Dignam et al. (16) . A 234-bp probe was prepared by PCR assay. The PCR product was purified with the Magic PCR Preps DNA purification system (Promega) and was end-labeled with 32 P. The labeled PCR product was digested with DNase I restriction endonuclease. Approximately 104 cpm of end-labeled, polyacrylamide gel-purified probe was incubated with RANKLinduced RAW264.7 cell nuclear extracts for 15 min on ice and then for 2 min at 25°C. DNase I (1 U/mL) was added for 1 min at 25°C and separated on an 8% (vol/vol) sequencing gel.
Northern Blotting Analysis. Northern blotting was performed as described previously (10, 17) . Total RNA (15 μg per lane) was isolated using TRIzol reagent (Life Technologies) (4). Human C/EBPα transcript (2.4 kb) and mouse C/EBPα transcript (2.7 kb) were used as C/EBPα-cDNA probes. Blots were stripped and rehybridized with 28S and GAPDH cDNA for normalization purposes.
Western Blotting Analysis. Western blotting was performed as described (4, 17) and visualized and quantified using a Fluor-S Multi-Imager and Multi-Analyst software (Bio-Rad). We used rabbit anti-Ctsk polyclonal antibody, which was previously generated in our laboratory (11) . We also used antibodies for C/EBPα, proviral integration 1 (PU.1), Finkel-Biskis-Jinkins osteosarcoma oncogene (c-fos), and nuclear factor of activated T cells cytoplasmic 1 (NFATc1) purchased from Santa Cruz Biotechnology. We performed a time-course Western blot analysis using antibodies for inhibitor of κBα (IκBα), phosphorylated (p)-IκBα, p38, p-p38, Iκκα, and p-Iκκαβ (Cell Signaling) in C/EBPα +/+ and C/EBPα −/− MBM cells cultured with M-CSF/RANKL for 0-60 min. We also performed a time-course Western blot analysis of C/EBPα expression in MBM after 0-120 h of M-CSF/RANKL induction. β-actin, GAPDH, and β-tubulin were used as controls.
Histological and Radiographic Procedures. Histological analyses were performed as described (n > 50) (7) . TNF receptor-associated protein 1 (TRAP) was used as a marker for OCs using a commercial kit (Sigma) according to the manufacturer's instructions. Multinucleated (more than three nuclei) TRAP + cells appear as dark purple cells and were counted by light microscopy (n > 50). Tibiae from C/EBPα +/+ and C/EBPα −/− mice were stained with Goldner's trichrome (n = 3); bright blue regions indicate mineralized tissue. For X-ray analysis, radiography was performed using a high-resolution soft X-ray system at 30 kV and high-speed holographic film (Kodak) (n = 5). Microcomputed tomography analysis was performed to determine the bone mass of fixed femora as described (18) by the University of Alabama at Birmingham Small Animal Bone Phenotyping Core associated with the Center for Metabolic Bone Disease (n = 3).
Immunostaining. Immunostaining was carried out as described (4) . Two specific antibodies, F4/80 (Biosource International) and CD11b (Pharmingen), were used as markers of monocyte/macrophage precursors as described previously (n > 9) (12, 19) . In addition, we used antibodies for C/EBPα, C/EBPβ, and C/EBPδ purchased from Santa Cruz Biotechnology, as well as antibodies for Ctsk as described above.
Immunofluorescence Analysis. We performed immunofluorescence analysis as we have previously described (3) , with the exception that we used anti-C/EBPα and anti-Ctsk as the primary antibodies purchased from Santa Cruz Biotechnology, and observations were performed by epifluorescence in a Zeiss axioplan microscope in the Developmental Neurobiology Imaging and Tissue Processing Core at the University of Alabama at Birmingham Intellectual and Disabilities Research Center. Nuclei were visualized with 1 μg/mL DAPI (Sigma). To visualize filamentous (F-actin) rings, MBM was stained with 2 U/mL Alexa Fluor 546-phalloidin (Molecular Probes) as previously described (20) . The experiments were set in triplicate on three independent occasions.
Real-Time Quantitative PCR and Semiquantitative PCR. Real-time (RT) quantitative PCR (qPCR) was performed as described (21, 22) using TaqMan probes purchased from Applied Biosystems as listed in Table S1 . Briefly, cDNA fragments were amplified by TaqMan Fast Advanced Master Mix (Applied Biosystems). Fluorescence from each TaqMan probe was detected by a Step-One RT-PCR system (Applied Biosystems). RNA samples were obtained from transduced MBM cultured with M-CSF alone, MBM-derived OC-like cells, MBM-derived monocyte/macrophage-like cells, or transfected uninduced RAW264.7 cells. The mRNA expression level of the housekeeping gene hypoxanthineguanine phosphoribosyl transferase (Hprt) was used as an endogenous control and enabled calculation of specific mRNA expression levels as a ratio of Hprt. Primer sequences used for semi-qPCR are listed in Table S1 . PCR conditions are available on request. Experiments were repeated at least three times.
Histomorphometric Analysis. Histomorphometric samples were processed as non-decalcified hard-tissue sections as described (7, 8) . Briefly, for quantitative bone volume histomorphometry, 5-μm sections of newborn C/EBPα −/− and C/EBPα +/+ mice were stained with Goldner's trichrome. For histomorphometric analysis of OC size and number, 10-μm sections of newborn C/EBPα −/− and C/EBPα +/+ mice were TRAP-stained without counterstaining. Histomorphometric analysis of these sections was performed using the National Institutes of Health ImageJ program. Eight parameters studied in this analysis are presented: bone volume relative to tissue volume, the percentage of OC surface area to total bone surface area of the tibiae, the percentage of osteoblast surface area to total bone surface area of the tibiae, OC numbers per bone perimeter, osteoblast numbers per bone perimeter, distal hypertrophic growth plate thickness, proximal hypertrophic growth plate thickness, and trabecular thickness. Large multinucleated cells with cytoplasmic vesicles and intimate contact to bone were considered as OCs, and cuboidal mononuclear cells in intimate contact with osteoid or bone were identified as osteoblasts. were seeded into the wells of a 12-well plate (without blood cells) and stimulated with 20 ng/mL M-CSF for 24 h. The attached cell number was confirmed to 60-70% of the total cell number. We used a retrovirus system to express C/EBPα ectopically in M-CSF-induced C/EBPα +/+ MBM cells as described (7) . We constructed a retrovirus vector (pBMN-C/EBPα) that was engineered to express both C/EBPα and GFP. The mouse C/EBPα cDNA was amplified and cloned into the pBMN retroviral vector (purchased from Addgene). We achieved retrovirus packaging by transducing pBMN into phoenix cells using the phoenix independent helper system. The viral supernatant was collected 52 h later. MBM cells were then transduced with the C/EBPα-expressing virus (pBMN-C/EBPα) or with a control virus (pBMN-GFP) overnight at 37°C as described (19) and stimulated with 20 ng/mL M-CSF for 24 h. Medium was replaced with fresh α-MEM with 10% (vol/vol) FBS and additionally stimulated with 20 ng/mL M-CSF for 96 h.
We similarly used a retrovirus system to express c-fos ectopically, as described previously (7), in C/EBPα −/− myeloid cells cultured with M-CSF/RANKL to induce osteoclastogenesis. We then quantified the number of multinucleated OCs as a percentage of the number of GFP + cells as described (7, 23) . C/EBPα was also overexpressed in uninduced RAW264.7 cells by plasmid stable transfection as described (12, 14) . C/EBPα cDNA (full-length cDNA from Open Biosystems) was cloned into the pCDNA3.1 expression vector (Invitrogen). RAW264.7 cells were transfected with pcDNA3.1-C/EBPα or with the vector control pcDNA3.1. RAW264.7 cells carrying pcDNA3.1-C/EBPα or the vector control pcDNA3.1 were passaged three times.
Promoter Analyses. For c-fos promoter luciferase promoter analyses, we used RAW264.7 cells maintained in DMEM high glucose containing 10% (vol/vol) FBS. Cells were cotransfected with increasing amounts of pcDNA3.1 (+) C/EBPα (0, 10, 30, or 100 ng per well), pSV-β-Galactosidase control vector (Promega) (50 ng per well), and GL3B, c-fos 1.1 kb, c-fos 0.48 kb, or c-fos 0.22 kb (50 ng per well) using the Lipofectamine transfection 2000 reagent (Invitrogen) and incubated for 6-8 h. Culture medium was replaced with fresh 10% (vol/vol) DMEM with M-CSF (10 ng/mL) and RANKL (10 ng/mL) and cultured for 3 d.
Luciferase activity was measured using a Steady-Glo luciferase assay system (Promega). PGL3 basic reporter vectors were used as controls (Promega). Luminescence was detected with a luminometer (BioTek Synergy 2). For ChIP analyses, MBM-derived monocytes and macrophages were differentiated in M-CSF (20 ng/ mL) for 24 h. Cells were further cultured for an additional 96 h in the presence of M-CSF (10 ng/mL)/RANKL (10 ng/mL) and C/ EBPα-specific antibodies (Santa Cruz Biotechnology). The output of ChIP assays was measured by qPCR and normalized by 10% (vol/vol) input. All assays were repeated at least three times. Fig. S1 . Ctsk critical cis-regulatory element (CCRE) contains a specific protein complex binding site that only binds to OC-like cell nuclear proteins (NPs). A gel mobility shift experiment was conducted using a 0-to 100-fold molar excess of 32 P-labeled −53 to −30 WT Ctsk promoter oligonucleotide probe in nuclear extracts prepared from RANKL-induced RAW264.7 cells. The WT Ctsk probe and RANKL-induced RAW264.7 cell nuclear extracts were incubated with unlabeled activator protein 1 (AP-1) at a 50-or 100-fold molar excess. The WT Ctsk probe and RANKL-induced RAW264.7 cell nuclear extracts were incubated with antibodies against C/EBPβ, C/EBPδ, or C/EBPα. , and TNF receptor-associated factor 6 (Traf6). *P < 0.05; **P < 0.01.
Fig. S3. Heterozygous C/EBPα
+/− femora exhibit increased bone density. X-ray analysis of femora indicates increased bone density in 8-mo-old C/EBPα +/− mice compared with C/EBPα +/+ mice of the same age (n = 3, repeated three times). The right column lists the probes for qRT-PCR while the left column lists the primer for semi-qPCR. The definitions for the gene symbols are as follows: Acp5: acid phosphatase 5, tartrate resistant; Calcr: calcitonin receptor; Car2: carbonic anhydrase 2; Cd68: CD68 antigen; Cebpa: CCAAT/enhancer binding protein (C/EBP), alpha; Cebpb: CCAAT/enhancer binding protein (C/EBP), beta; Csf1r (CD115): colony stimulating factor 1 receptor; Ctsk: cathepsin K; Emr1 (F4/80): EGF-like module containing, mucin-like, hormone receptor-like sequence 1; Fos (c-Fos): FBJ osteosarcoma oncogene; Hprt: hypoxanthine guanine phosphoribosyl transferase; Itgam (CD11b): integrin alpha M; Itgb3: integrin beta 3; MMP14: matrix metallopeptidase 14; Mmp9: matrix metallopeptidase 9; Mst1r: macrophage stimulating 1 receptor (c-met-related tyrosine kinase); Myo1D: myosin ID; Nfatc1: nuclear factor of activated T-cells, cytoplasmic, calcineurindependent 1; Oscar: osteoclast associated receptor; Pparg: peroxisome proliferator activated receptor gamma; Rcan2: regulator of calcineurin 2; Runx2: runt related transcription factor 2; Sfpi1 (PU.1): SFFV proviral integration 1; Tfrc (CD71): transferrin receptor; TNFalpha: tumor necrosis factor; Tnfrsf11a: tumor necrosis factor receptor superfamily, member 11a; Traf6: TNF receptor-associated factor 6.
